Kaken Pharmaceutical Co., Ltd. 4521.T Stock
Kaken Pharmaceutical Co., Ltd. Price Chart
Kaken Pharmaceutical Co., Ltd. 4521.T Financial and Trading Overview
Kaken Pharmaceutical Co., Ltd. stock price | 3432 JPY |
Previous Close | 3601 JPY |
Open | 3602 JPY |
Bid | 3673 JPY x 0 |
Ask | 3683 JPY x 0 |
Day's Range | 3601 - 3682 JPY |
52 Week Range | 3485 - 4075 JPY |
Volume | 249K JPY |
Avg. Volume | 84.91K JPY |
Market Cap | 137.94B JPY |
Beta (5Y Monthly) | 0.320306 |
PE Ratio (TTM) | 16.240183 |
EPS (TTM) | 78.73 JPY |
Forward Dividend & Yield | 150 (4.13%) |
Ex-Dividend Date | September 28, 2023 |
1y Target Est | 3500 JPY |
4521.T Valuation Measures
Enterprise Value | 65.83B JPY |
Trailing P/E | 16.240183 |
Forward P/E | 21.413614 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 1.8899773 |
Price/Book (mrq) | 1.0124143 |
Enterprise Value/Revenue | 0.902 |
Enterprise Value/EBITDA | 6.229 |
Trading Information
Kaken Pharmaceutical Co., Ltd. Stock Price History
Beta (5Y Monthly) | 0.320306 |
52-Week Change | -2.93% |
S&P500 52-Week Change | 20.43% |
52 Week High | 4075 JPY |
52 Week Low | 3485 JPY |
50-Day Moving Average | 3679.4 JPY |
200-Day Moving Average | 3757.03 JPY |
4521.T Share Statistics
Avg. Volume (3 month) | 84.91K JPY |
Avg. Daily Volume (10-Days) | 99.21K JPY |
Shares Outstanding | 37.47M |
Float | 33.71M |
Short Ratio | N/A |
% Held by Insiders | 13.20% |
% Held by Institutions | 30.86% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | 328.00% |
Payout Ratio | 0.6657 |
Last Split Factor | 1:2 |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | 7.45% |
Operating Margin (ttm) | 10.96% |
Gross Margin | 54.19% |
EBITDA Margin | 14.47% |
Management Effectiveness
Return on Assets (ttm) | 3.01% |
Return on Equity (ttm) | 3.95% |
Income Statement
Revenue (ttm) | 72.98B JPY |
Revenue Per Share (ttm) | 1942.55 JPY |
Quarterly Revenue Growth (yoy) | -5.00000000000000000000000000000000% |
Gross Profit (ttm) | N/A |
EBITDA | 10.57B JPY |
Net Income Avi to Common (ttm) | 5.44B JPY |
Diluted EPS (ttm) | 226.66 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 74.26B JPY |
Total Cash Per Share (mrq) | 1981.54 JPY |
Total Debt (mrq) | 3.85B JPY |
Total Debt/Equity (mrq) | 2.81 JPY |
Current Ratio (mrq) | 5.274 |
Book Value Per Share (mrq) | 3635.863 |
Cash Flow Statement
Operating Cash Flow (ttm) | 9.25B JPY |
Levered Free Cash Flow (ttm) | 7.49B JPY |
Profile of Kaken Pharmaceutical Co., Ltd.
Country | Japan |
State | N/A |
City | Tokyo |
Address | 28-8, Honkomagome 2-chome |
ZIP | 113-8650 |
Phone | 81 3 5977 5001 |
Website | https://www.kaken.co.jp |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast Spray, a wound-healing agent; Ebrantil, an anti-dysuria agent; Ecclock gel for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surgery and gynecology to reduce complications from post-operative adhesions. It also provides agrochemicals and animal health products, including Polyoxins that is used as fungicide; Pentoxazone and Metamifop rice herbicides; Salinomycin, an anti-coccidial feed additive for chickens; and Uroston, urinary stone dissolution and elimination acceleration agent for cattle. In addition, the company is developing KMW-1 for the removal of eschar; KAR, which is in phase III clinical trial for the treatment of head lice; ART-001 that is in phase II clinical trial for the treatment of refractory vascular malformations; ART-648, which is in phase II clinical trial for the treatment of bullous pemphigoid; BBI-4000 that is in phase I clinical trial for primary palmoplantar hyperhidrosis; KP-483, which is in phase I clinical trial for the treatment of solid tumors; and NM26-2198 that is in phase I clinical trial for the treatment of atopic dermatitis. Further, it is involved in the rental of Bunkyo Green Court. Kaken Pharmaceutical Co., Ltd. was founded in 1917 and is headquartered in Tokyo, Japan.
Q&A For Kaken Pharmaceutical Co., Ltd. Stock
What is a current 4521.T stock price?
Kaken Pharmaceutical Co., Ltd. 4521.T stock price today per share is 3432 JPY.
How to purchase Kaken Pharmaceutical Co., Ltd. stock?
You can buy 4521.T shares on the Tokyo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Kaken Pharmaceutical Co., Ltd.?
The stock symbol or ticker of Kaken Pharmaceutical Co., Ltd. is 4521.T.
Which industry does the Kaken Pharmaceutical Co., Ltd. company belong to?
The Kaken Pharmaceutical Co., Ltd. industry is Drug Manufacturers-Specialty & Generic.
How many shares does Kaken Pharmaceutical Co., Ltd. have in circulation?
The max supply of Kaken Pharmaceutical Co., Ltd. shares is 37.87M.
What is Kaken Pharmaceutical Co., Ltd. Price to Earnings Ratio (PE Ratio)?
Kaken Pharmaceutical Co., Ltd. PE Ratio is 43.59202200 now.
What was Kaken Pharmaceutical Co., Ltd. earnings per share over the trailing 12 months (TTM)?
Kaken Pharmaceutical Co., Ltd. EPS is 78.73 JPY over the trailing 12 months.
Which sector does the Kaken Pharmaceutical Co., Ltd. company belong to?
The Kaken Pharmaceutical Co., Ltd. sector is Healthcare.
Kaken Pharmaceutical Co., Ltd. 4521.T included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Developed ex US SC NTR G NQDMXUSSCGBPN | 1704.47 GBP 2179.91 USD |
0
|
— — | 1704.47 GBP 2179.91 USD | 1704.47 GBP 2179.91 USD | — - | — — |
- {{ link.label }} {{link}}